Penile cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5, 2013, Pages 594-615

  Clark, Peter E ^a   Spiess, Philippe E ^c   Agarwal, Neeraj ^b   Biagioli, Matthew C ^c   Eisenberger, Mario A ^d   Greenberg, Richard E ^e   Herr, Harry W ^f   Inman, Brant A ^g   Kuban, Deborah A ^h   Kuzel, Timothy M ⁱ   Lele, Subodh M ^j   Michalski, Jeff ^k   Pagliaro, Lance ^h   Pal, Sumanta K ^l   Patterson, Anthony ^m   Plimack, Elizabeth R ^e   Pohar, Kamal S ⁿ   Porter, Michael P ^o   Richie, Jerome P ^p   Sexton, Wade J ^c   Shipley, William U ^q   Small, Eric J ^r   Trump, Donald L ^s   Wile, Geoffrey ^a   Wilson, Timothy G ^l   Dwyer, Mary ^t   Ho, Maria ^t   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DUKE CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j NEBRASKA MEDICAL CENTER   (United States)

^k BARNES JEWISH HOSPITAL   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁿ OHIO STATE UNIVERSITY   (United States)

^o UNIVERSITY OF WASHINGTON   (United States)

^p Dana Farber/Brigham and Women's Cancer Center   (United States)

^q MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; PANITUMUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTINUOUS INFUSION; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; PENIS AMPUTATION; PENIS CANCER; PRACTICE GUIDELINE; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; UNITED STATES; CANCER STAGING; FOLLOW UP; MALE; METASTASIS; PENILE NEOPLASMS; RECURRENT DISEASE; RISK FACTOR; PENIS TUMOR;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PENILE NEOPLASMS; RECURRENCE; RISK FACTORS;

EID: 84877932759     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0075     Document Type: Article

References (106)

1. Pettaway CA, Lynch D Jr, Davis D. Tumors of the penis. In: Wein AJ, Kavoussi L, Novick AC, et al, eds. Campbell-Walsh Urology, 9th ed. Philadelphia: Saunders; 2007:959-992.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
3. Pow-Sang MR, Ferreira U, Pow-Sang JM, et al. Epidemiology and natural history of penile cancer. Urology 2010;76:S2-6.
4. Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int 2001;88:473-483.
5. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008;113:2883-2891.
6. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000:189-193.
7. Sufrin G, Huben R. Benign and malignant lesions of the penis. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW, eds. Adult and Pediatric Urology, 2nd ed. Chicago: Mosby Year Book Medical Publishers; 1991:1997-2042.
8. Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005;116:606-616.
9. Sarkar FH, Miles BJ, Plieth DH, Crissman JD. Detection of human papillomavirus in squamous neoplasm of the penis. J Urol 1992;147:389-392.
10. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654.
11. Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993;85:19-24.
12. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int 2000;86:459-465.
13. Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol 2006;54:369-391.
14. Barbagli G, Palminteri E, Mirri F, et al. Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey. J Urol 2006;175:1359-1363.
15. Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990;322:1093-1097.
16. Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009;27:141-150.
17. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
18. Cubilla AL, Reuter V, Velazquez E, et al. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol 2001;9:111-120.
19. Guimaraes GC, Cunha IW, Soares FA, et al. Penile squamous cell carcinoma clinicopathological features, nodal metastasis and outcome in 333 cases. J Urol 2009;182:528-534.
20. Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology 2010;76:S66-73.
21. Barocas DA, Chang SS. Penile cancer: clinical presentation, diagnosis, and staging. Urol Clin North Am 2010;37:343-352.
22. Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol 2008;180:933-938.
23. Leijte JA, Horenblas S. Shortcomings of the current TNM classification for penile carcinoma: time for a change? World J Urol 2009;27:151-154.
24. Sobin LH, Wittekind C, International Union against Cancer. TNM Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss; 2002.
25. Slaton JW, Morgenstern N, Levy DA, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol 2001;165:1138-1142.
26. Velazquez EF, Ayala G, Liu H, et al. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008;32:974-979.
27. Pizzocaro G, Algaba F, Horenblas S, et al. EAU penile cancer guidelines 2009. Eur Urol 2010;57:1002-1012.
28. Lont AP, Besnard AP, Gallee MPW, et al. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int 2003;91:493-495.
29. Choi JW, Choi M, Cho KH. A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision. Ann Dermatol 2009;21:419-422.
30. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002;46:545-548.
31. Taliaferro SJ, Cohen GF. Bowen's disease of the penis treated with topical imiquimod 5% cream. J Drugs Dermatol 2008;7:483-485.
32. Feldman AS, McDougal WS. Long-term outcome of excisional organ sparing surgery for carcinoma of the penis. J Urol 2011;186:1303-1307.
33. Bandieramonte G, Colecchia M, Mariani L, et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol 2008;54:875-882.
34. Horenblas S, van Tinteren H, Delemarre JF, et al. Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 1992;147:1533-1538.
35. Morelli G, Pagni R, Mariani C, et al. Glansectomy with split-thickness skin graft for the treatment of penile carcinoma. Int J Impot Res 2009;21:311-314.
36. O'Kane HF, Pahuja A, Ho KJ, et al. Outcome of glansectomy and skin grafting in the management of penile cancer. Adv Urol 2011;2011:240824.
37. Pietrzak P, Corbishley C, Watkin N. Organ-sparing surgery for invasive penile cancer: early follow-up data. BJU Int 2004;94:1253-1257.
38. Hatzichristou DG, Apostolidis A, Tzortzis V, et al. Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumors of the penis. Urology 2001;57:966-969.
39. Bissada NK, Yakout HH, Fahmy WE, et al. Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma. J Urol 2003;169:500-502.
40. Frimberger D, Hungerhuber E, Zaak D, et al. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol 2002;168:2418- 2421.
41. Azrif M, Logue JP, Swindell R, et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol) 2006;18:320- 325.
42. Crook J, Grimard L, Tsihlias J, et al. Interstitial brachytherapy for penile cancer: an alternative to amputation. J Urol 2002;167:506-511.
43. Rozan R, Albuisson E, Giraud B, et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995;36:83-93.
44. Zouhair A, Coucke PA, Jeanneret W, et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer 2001;37:198-203.
45. Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009;27:189-196.
46. Horenblas S, van Tinteren H. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol 1994;151:1239-1243.
47. Minhas S, Kayes O, Hegarty P, et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005;96:1040-1043.
48. de Crevoisier R, Slimane K, Sanfilippo N, et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 2009;74:1150-1156.
49. Crook J, Jezioranski J, Cygler JE. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy 2010;9:151-158.
50. Heyns CF, Fleshner N, Sangar V, et al. Management of the lymph nodes in penile cancer. Urology 2010;76:43-57.
51. Solsona E, Algaba F, Horenblas S, et al. EAU Guidelines on Penile Cancer. Eur Urol 2004;46:1-8.
52. Kroon BK, Valdes Olmos RA, van Tinteren H, et al. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with penile carcinoma. J Urol 2005;174:2214-2217.
53. Hughes B, Leijte J, Shabbir M, et al. Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol 2009;27:197-203.
54. Mueller-Lisse UG, Scher B, Scherr MK, Seitz M. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol 2008;18:105-110.
55. Scher B, Seitz M, Albinger W, et al. Value of PET and PET/CT in the diagnostics of prostate and penile cancer. Recent Results Cancer Res 2008;170:159-179.
56. Scher B, Seitz M, Reiser M, et al. 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 2005;46:1460-1465.
57. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 2005;174:923-927.
58. Caso JR, Rodriguez AR, Correa J, Spiess PE. Update in the management of penile cancer. Int Braz J Urol 2009;35:406-415.
59. Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol 1997;32:5-15.
60. Solsona E, Iborra I, Rubio J, et al. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol 2001;165:1506-1509.
61. Villavicencio H, Rubio-Briones J, Regalado R, et al. Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur Urol 1997;32:442-447.
62. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466.
63. Pettaway CA, Pisters LL, Dinney CP, et al. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 1995;154:1999-2003.
64. Leijte JA, Kroon BK, Valdes Olmos RA, et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol 2007;52:170-177.
65. Valdes Olmos RA, Tanis PJ, Hoefnagel CA, et al. Penile lymphoscintigraphy for sentinel node identification. Eur J Nucl Med 2001;28:581-585.
66. Gonzaga-Silva LF, Tavares JM, Freitas FC, et al. The isolated gamma probe technique for sentinel node penile carcinoma detection is unreliable. Int Braz J Urol 2007;33:58-63.
67. Kroon BK, Horenblas S, Meinhardt W, et al. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. Eur Urol 2005;47:601-606.
68. Spiess PE, Izawa JI, Bassett R, et al. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 2007;177:2157-2161.
69. Tanis PJ, Lont AP, Meinhardt W, et al. Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol 2002;168:76-80.
70. Kroon BK, Horenblas S, Estourgie SH, et al. How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol 2004;171:2191-2194.
71. Kroon BK, Horenblas S, Deurloo EE, et al. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005;95:517-521.
72. Crawshaw JW, Hadway P, Hoffland D, et al. Sentinel lymph node biopsy using dynamic lymphoscintigraphy combined with ultrasound-guided fine needle aspiration in penile carcinoma. Br J Radiol 2009;82:41-48.
73. Hadway P, Smith Y, Corbishley C, et al. Evaluation of dynamic lymphoscintigraphy and sentinel lymph-node biopsy for detecting occult metastases in patients with penile squamous cell carcinoma. BJU Int 2007;100:561-565.
74. Ficarra V, Galfano A. Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma? Eur Urol 2007;52:17-19.
75. Stancik I, Holtl W. Penile cancer: review of the recent literature. Curr Opin Urol 2003;13:467-472.
76. Kroon BK, Horenblas S, Lont AP, et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005;173:816-819.
77. McDougal WS. Preemptive lymphadenectomy markedly improves survival in patients with cancer of the penis who harbor occult metastases. J Urol 2005;173:681.
78. Sharp DS, Angermeier KW. Surgery of penile and urethral carcinoma. In: Wein AJ, Kavoussi L, Novick AC, et al, eds. Campbell-Walsh Urology, 9th ed. Philadelphia: Saunders; 2007:993-1022.
79. Catalona WJ. Re: Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol 1988;140:836.
80. Lopes A, Rossi BM, Fonseca FP, Morini S. Unreliability of modified inguinal lymphadenectomy for clinical staging of penile carcinoma. Cancer 1996;77:2099-2102.
81. Protzel C, Alcaraz A, Horenblas S, et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol 2009;55:1075- 1088.
82. Bermejo C, Busby JE, Spiess PE, et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007;177:1335-1338.
83. Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol 2009;27:221-225.
84. Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 2009;27:205-212.
85. Lont AP, Kroon BK, Gallee MP, et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007;177:947-952.
86. Tobias-Machado M, Tavares A, Molina WR, et al. Video endoscopic inguinal lymphadenectomy (VEIL): minimally invasive resection of inguinal lymph nodes. Int Braz J Urol 2006;32:316-321.
87. Tobias-Machado M, Tavares A, Ornellas AA, et al. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol 2007;177:953-957.
88. Tobias-Machado M, Tavares A, Silva MN, et al. Can video endoscopic inguinal lymphadenectomy achieve a lower morbidity than open lymph node dissection in penile cancer patients? J Endourol 2008;22:1687-1691.
89. Bishoff JT, Lackland AF, Basler JW, et al. Endoscopic subcutaneous modified inguinal lymph node dissection (ESMIL) for squamous cell carcinoma of the penis. J Urol 2003;169(Suppl):78.
90. Sotelo R, Sanchez-Salas R, Carmona O, et al. Endoscopic lymphadenectomy for penile carcinoma. J Endourol 2007;21:364- 367.
91. Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999;161:1823- 1825.
92. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010;28:3851-3857.
93. Theodorescu D, Russo P, Zhang ZF, et al. Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 1996;155:1626-1631.
94. Leijte JA, Hughes B, Graafland NM, et al. Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol 2009;27:3325-3329.
95. Lont AP, Horenblas S, Tanis PJ, et al. Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol 2003;170:783-786.
96. Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008;54:161-168.
97. Chaux A, Reuter V, Lezcano C, et al. Comparison of morphologic features and outcome of resected recurrent and nonrecurrent squamous cell carcinoma of the penis: a study of 81 cases. Am J Surg Pathol 2009;33:1299-1306.
98. Ornellas AA, Nobrega BL, Wei Kin Chin E, et al. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol 2008;180:1354-1359.
99. Graafland NM, Moonen LM, van Boven HH, et al. Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for management. J Urol 2011;185:888-893.
100. Lopes A, Bezerra AL, Serrano SV, Hidalgo GS. Iliac nodal metastases from carcinoma of the penis treated surgically. BJU Int 2000;86:690-693.
101. Pow-Sang JE, Benavente V, Pow-Sang JM, Pow-Sang M. Bilateral ilioinguinal lymph node dissection in the management of cancer of the penis. Semin Surg Oncol 1990;6:241-242.
102. Ravi R. Morbidity following groin dissection for penile carcinoma. Br J Urol 1993;72:941-945.
103. Sanchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 2004;22:236-244.
104. Srinivas V, Morse MJ, Herr HW, et al. Penile cancer: relation of extent of nodal metastasis to survival. J Urol 1987;137:880-882.
105. Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol 2003;170:359-365.
106. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010;76:58-65.